A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HP-Beta-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Adrabetadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Biomarker; Pharmacokinetics
- Sponsors CTD Holdings
- 30 Apr 2018 According to a CTD Holdings media release, FDA has authorized application for extension study of this trial.
- 29 Mar 2018 According to a CTD Holdings media release, initial review of safety data for this study has been completed.
- 21 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Feb 2019.